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ABSTRACT	 	In	the	past	few	decades,	considerable	attention	has	been	focused	on	the	development	of	new	drug	delivery	system	(NDDS).	The	NDDS	should	ideally	fulfill	two	prerequisites.	Firstly,	it	should	deliver	the	drug	at	a	rate	directed	by	the	needs	of	the	body,	over	the	period	of	treatment.	Secondly,	it	should	channel	the	active	entity	to	the	site	of	action.	Conventional	dosage	forms	including	prolonged	release	dosage	forms	are	unable	to	meet	none	of	these.	At	present,	no	available	drug	delivery	system	behaves	ideally,	but	sincere	attempts	have	been	made	to	achieve	them	through	various	novel	approaches	in	drug	delivery.	The	aim	of	present	work	is	to	develop	a	niosomal	drug	delivery	system	of	aceclofenac.	To	perform	drug-polymer	compatibility	FT-IR	studies	were	carried	out	and	observed	that	there	was	no	interaction	between	the	APl	and	excipients.	8	nio-somal	formulations	are	prepared	by	the	thin	film	hydration	method	using	the	cholesterol	as	the	phospho-lipid.	Prepared	niosomal	formulations	were	characterized	by	vesicle	size,	shape,	surface	charge,	entrapment	efficiency,	drug	content	and	invitro	drug	release	studies.	The	vesicle	size,	size	distribution	and	zeta	potential	of	the	optimized	formulation	(F5)	was	found	to	be	65.6	nm	and	zeta	potential	was	found	to	be	-1.5mV.	Size	distribution	curve	confirms	the	normal	size	distribution	of	the	vesicles.	The	%	entrapment	efficiency	of	ni-osomal	vesicles	formulations	were	found	to	be	in	the	range	of	54.18±0.59	to	92.71±0.56	and	optimized	for-mulation	was	 found	to	be	92.71±0.56	and	drug	content	of	niosomes	formulations	(F1to	F8)	were	deter-mined	to	be	in	the	range	of	94.6	-97.8%.	The	pH	of	all	topical	niosomal	gels	were	found	to	be	in	the	range	of	7.4±0.02	to	7.4±0.08.The	best	fit	with	higher	correlation	(r2>	0.99)	was	found	with	the	Zero	Order	Release	and	follows	Korsemeyer	peppas	equation	for	all	the	formulations,	which	means	that	release	of	Aceclofenac	from	the	lipid	bilayer	vesicles	were	due	to	diffusion.	The	stability	studies	were	carried	out	and	there	was	no	significant	change	found	in	the	formulations.	
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INTRODUCTION	In	 the	past	 few	decades,	 considerable	attention	has	been	focused	on	the	development	of	new	drug	deliv-ery	 system	 (NDDS).	 The	NDDS	 should	 ideally	 fulfill	two	prerequisites.	Firstly,	 it	should	deliver	the	drug	at	a	rate	directed	by	the	needs	of	the	body,	over	the	period	of	treatment.	Secondly,	it	should	channel	the	active	entity	to	the	site	of	action.	Conventional	dosage	forms	including	prolonged	release	dosage	forms	are	unable	to	meet	none	of	these.	At	present,	no	available	drug	delivery	system	behaves	ideally,	but	sincere	at-tempts	have	been	made	to	achieve	them	through	var-ious	novel	approaches	in	drug	delivery[1].	Approaches	are	being	adapted	to	achieve	this	goal,	by	paying	con-siderable	attention	either	to	control	the	distribution	of	drug	by	incorporating	it	in	a	carrier	system,	or	by	altering	 the	 structure	 of	 the	 drug	 at	 the	molecular	level,	or	to	control	the	input	of	the	drug	into	the	bio-environmental	 to	 ensure	 an	 appropriate	 profile	 of	distribution[2].Niosomes	or	nonionic	surfactant	vesi-cles	 are	microscopic	 lamellar	 structures	 formed	 on	admixture	of	nonionic	surfactant	of	the	alkyl	or	dial-
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kyl	polyglycerol	ether	class	and	cholesterol	with	sub-sequent	hydration	in	aqueous	media[3].	In	niosomes,	the	vesicles	forming	amphiphile	is	a	nonionic	surfac-tant	such	as	spans,	tweens	which	is	usually	stabilized	by	addition	of	cholesterol	and	small	amount	of	charge	inducer	 such	 as	 dicetyl	 phosphate[4].Niosomes	 can	entrap	both	hydrophilic	and	lipophilic	drugs,	either	in	aqueous	layer	or	in	vesicular	membrane	made	of	lipid	materials.	Because	of	the	presence	of	nonionic	surfac-tant	with	the	lipid,	there	is	better	targeting	of	drugs	to	tumors,	 liver	and	brain.	 It	may	prove	very	useful	for	targeting	the	drug	for	treating	cancers,	parasitic,	viral	and	other	microbial	disease	more	effectively[5].	
MATERIALS	AND	METHODS	Aceclofenac	was	a	gift	sample	from	wockhardt	phar-maceutics	and	spans,	cholesterol,	carbopol	were	ob-tained	from	Loba	Chemie,	Mumbai.	All	other	chemi-cals	used	were	of	analytical	grade.	
	Pre	formulation	parameters	
Standard	calibration	curve	of	the	Aceclofenac	100mg	of	accurately	weighed	Aceclofenac	in	100ml	of	methanol	 (stock	 solution-1).	 It	 contains	 1mg/ml	 of	drug.	 From	 stock	 solution-1,	 2ml	 of	 solution	 was	taken	into	a	100ml	volumetric	flask	and	volume	was	made	up	with	phosphate	buffer	pH	7.4	 (stock	 solu-tion-2).	 It	 contains	 20µg/ml.	 From	 this	 stock	 solu-tion-2,	pipette	out	1,	2,	3,	4,	5,	and	6ml	were	taken	in	10ml	volumetric	flask	and	make	up	with	7.4	pH	phos-phate	buffer.	It	contains	2,	4,	6,	8,	10	and	12µg/ml	re-spectively.	 The	 absorption	 maxima	 obtained	 at	275nm	and	absorbances	were	detected	by	using	UV-visible	spectrophotometer[6].		
Table 1: Calibration table of aceclofenac 
S.No	 Concentration	 Absorbance	1	 0	 0	2	 2	 0.1374	3	 4	 0.2604	4	 6	 0.3912	5	 8	 0.5188	6	 10	 0.6425	
 
Figure 1: Calibration curve of aceclofenac	
Fourier	Transform	Infrared	Spectroscopy	(FT-IR)		Fourier	 transform	IR	spectra	were	obtained	on	Shi-madzu	FT-IR	spectrometer.	Samples	were	prepared	
in	KBr	disks	(2mg	sample	in	200mg	KBr).	The	scan-ning	range	was	450-4000	cm-1	and	the	resolution	was	4	cm-1.	
 
Figure 2: FTIR spectra of Aceclofenac pure drug 
 
Figure 3: FTIR spectra of optimized niosomal formula-
tion 
Preparation	of	Aceclofenac	Niosomes[7]	Aceclofenac	niosomes	were	prepared	using	thin	film-hydration	method.	Accurately	weighed	quantities	of	the	surfactant	(SpanTM))	and	cholesterol	in.	1:1	and	1:2	ratios	were	dissolved	in	8	ml	of	chloroform:meth-anol	mixture	(2:1,	v/v)	in	a	round-bottom	flask.	After-wards,	Aceclofenac	dissolved	in	5mL	of	chloroform:	methanol	mixture	 (2:1,	 v/v)	was	added	 to	 the	 lipid	solution	 (Table	 1).	 The	 organic	 solvents	 were	 re-moved	under	vacuum	in	a	rotary	evaporator	at	40	◦C	for	20	min	to	form	a	thin	film	on	the	wall	of	the	flask,	and	kept	in	a	desiccator	under	vacuum	for	2	hours	en-sure	 total	 removal	 of	 trace	 solvents.	 After	 removal	solvents	hydration	of	the	surfactant	film	was	carried	out	using	10mL	of	distilled	water	at	55	◦C,	which	 is	above	 the	 gel–liquid	 transition	 temperature	 (Tc)	 of	sorbitan	monoesters	and	polyoxyethylene	alkyl	ether	surfactants.	The	 resulting	niosomal	 suspension	was	mechanically	 shaken	 for	1	h	using	a	horizontal	me-chanical	shaking	water	bath	at	550C.	Then,	the	vesicle	suspension	was	sonicated	in	3	cycles	of	1min	“on”	and	1min	“off”	 leading	to	the	formation	of	multilamellar	niosomes.	The	niosomal	suspension	was	 left	 to	ma-ture	overnight	at	4	◦C	and	stored	at	refrigerator	tem-perature	for	further	studies.		
Preparation	of	aceclofenac	niosomal	gel[8]	Niosomes	 aqueous	 dispersion	 was	 utilized	 for	 the	formulation	of	topical	gel.	Gel	polymer	such	as	carbo-pol-934	was	 utilized	 to	 prepare	 niosome	 gel.	 2g	 of	carbopol-934	powder	was	dispersed	into	vigorously	
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stirred	and	allowed	to	hydrate	for	24	hrs.	Later	10ml	of	 Propylene	 glycol	was	 added.	The	dispersion	was	neutralized	with	 the	drop	wise	addition	of	10%	so-dium	hydroxide,	mixing	was	continued	until	a	trans-parent	 gel	was	 appeared.	 Then	 the	 amount	 of	 base	was	adjusted	to	achieve	a	gel	with	pH	6.5	 .It	can	be	measured	by	using	pH	meter.	
Evaluation	of	Niosomal	gel	
Size	and	size	distribution:	Size	and	size	distribution	studies	were	done	for	niosomes	prepared	from	Nio-somes	hydration.	The	Niosomal	suspension	(100	mg)	was	hydrated	in	a	small	glass	test	tube	using	10	ml	of	pH	7.4	phosphate	buffer	solution.	The	dispersion	was	observed	under	optical	microscope	at	40X	magnifica-tion.	Size	and	size	distribution	of	200–300	niosomes	were	 noted	 using	 calibrated	 stage	 and	 ocular	 mi-crometers	(Elico	Instruments,	Hyderabad).	Similarly,	size	was	noted	 for	niosomes	 formed	spontaneously	from	Niosomes	after	hydration	without	agitation	in	a	cavity	slide	(B.	Vora	et	al.,	1998).	
 
Figure 4: Photomicrograph of Aceclofenac loaded noi-
some (F5) at 10X	
 
Figure 5: SEM Micrograph of Niosomes (F5)	
Entrapment	efficiency	
To	0.2	g	of	Niosomal	gel,	weighed	in	a	glass	tube,	10	ml	phosphate	buffer	pH	7.4	was	added.	The	aqueous	suspension	was	then	sonicated.	Niosomes	containing	aceclofenac	were	separated	from	untrapped	drug	by	centrifugation	at	9000rpm	for	45	min	at	4	◦C.	The	su-pernatant	 was	 recovered	 and	 assayed	 spectro-photmetrically	 using	 UV	 spectrophotometer	 at	283nm.		The	encapsulation	percentage	of	drug	(EP)	was	calcu-lated	by	the	following	equation	EP = $(𝐶') − 𝐶*𝐶' + × 100	where,	Ct,	concentration	of	total	Aceclofenac	,	Cr,	con-centration	of	free	Aceclofenac	.	
Vesicle	physical	analysis	The	shape,	surface	characteristics,	and	size	of	the	ni-osomes	were	observed	by	scanning	electron	micros-copy.	Once	again,	0.2	g	of	the	Niosome	gel	in	a	glass	tube	 was	 diluted	 with	 10	 ml	 of	 pH	 7.4	 phosphate	buffer.	The	niosomes	were	mounted	on	an	aluminum	stub	using	double-sided	adhesive	carbon	tape.	Then	the	vesicles	were	sputter-coated	with	gold	palladium	(Au/Pd)	using	a	vacuum	evaporator	(Edwards)	and	examined	using	a	scanning	electron	microscope	(Hi-tachi	3700N,	Germany)	equipped	with	a	digital	cam-era,	at	10	kV	accelerating	voltage.	
Viscosity	determination	The	viscosity	of	the	optimized	formulations	was	de-termined	by	using	rotational	viscometer	(Brookfield	viscometer,	DV-II,	USA).	The	sample	(100	g)	was	al-lowed	 to	 equilibrate	 for	 5	 min	 after	 placing	 in	 a	beaker	and	dial	reading	was	measured	using	62	spin-dle	at	0.3,	0.6	&	1.5	rpm.	The	measurements	were	car-ried	in	duplicate	at	ambient	temperature	(Maria	et	al.,	2009).	
Ex-Vivo	Release	Study	Ex	vivo	release	studies	were	carried	out	using	unjack-eted	 vertical	 franz	 diffusion	 cells	with	 a	 diffusional	surface	area	of	6.154	cm2	and	20	mL	of	receptor	cell	volume.	 Prior	 to	 the	 study,	 the	 dialysis	 membrane	(Himedia	laboratories	Pvt	Ltd.,	Mumbai)	was	soaked	
Table 2: Composition of Aceclofenac niosomes (F1 to F8) 
Ingredients (%) F1 F2 F3 F4 F5 F6 F7 F8 
Aceclofenac 25 25 25 25 25 25 25 25 
Cholesterol 38.6 38.6 38.6 38.6 77.2 77.2 77.2 77.2 
Span 20 34.6 - - - 34.6 - - - 
Span 40 - 40.2 - - - 40.2 - - 
Span 60 - - 43.6 - - - 43.6 - 
Span 80 - - - 46.3 - - - 46.3 
Carbopol 934 in % 2 2 2 2 2 2 2 2 
Aceclofenac 25 25 25 25 25 25 25 25 
Cholesterol 38.6 38.6 38.6 38.6 77.2 77.2 77.2 77.2 
Span 20 34.6 - - - 34.6 - - - 
Span 40 - 40.2 - - - 40.2 - - 
 
Table 3: 
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in	phosphate	buffer	pH	7.4	Formulation	equivalent	to	5mg	of	Aceclofenac	was	placed	in	the	donor	compart-ment.	The	receptor	compartment	consisting	of	PB	pH	7.4	(containing	0.02%	w/v	of	ethanol	to	retard	micro-bial	 growth)	was	maintained	 at	 37±2°C	 under	 con-stant	stirring	upto	24	hrs	 .	The	donor	chamber	and	the	sampling	port	were	covered	with	 lid	 to	prevent	evaporation	during	the	study.	Aliquots	of	5	mL	were	withdrawn	 periodically	 at	 different	 time	 intervals	(0.25,	0.5,	1,	1.5,	2,	3,	4,	6,	8,	10,	12,	and	24	hrs)	and	replaced	with	equal	volume	to	maintain	constant	re-ceptor	phase	volume.	At	the	end	of	the	study,	the	sam-ples	were	 suitably	 diluted	 and	 the	 amount	 of	 drug	was	determined	spectrophotmetrically	at	275	nm.	
Stability	Studies	The	 formulations	 stored	 in	glass	vials	 covered	with	aluminum	foil	were	kept	at	room	temperature	and	in	refrigerator	(4◦C)	for	a	period	of	30	days.	At	definite	time	 intervals	 (10,	 20,	 and	 30	 days),	 samples	were	withdrawn	 and	 hydrated	 with	 phosphate-buffered	saline	 (pH	 7.4)	 and	 observed	 for	 any	 sign	 of	 drug	
crystallization	 under	 optical	 microscope.	 Further-more,	 the	 samples	were	 also	 evaluated	 for	 particle	size	and	percent	retention	of	Aceclofenac.	
RESULTS	AND	DISCUSSION	
Entrapment	 efficiency:	 The	 %	 entrapment	 effi-ciency	of	niosomal	vesicles	formulations	were	found	to	be	 in	 the	range	of	54.18±0.59	 to	92.71±0.56.	En-trapment	 efficiency	 of	 the	 F5	 formulation	was	 high	(maximum	92.71±0.56	for	F5).	
Table 6: Drug entrapped and % Drug content in nio-
somes 
Formulation % Entrapment Efficiency 
F1 77.12±1.05 
F2 88.50±0.83 
F3 63.19±0.96 
F4 67.66±0.69 
F5 92.71±0.56 
F6 59.44±0.33 
F7 80.24±0.48 
F8 54.18±0.59 
Table 4: In-Vitro drug release of Niosomes gel (F1to F8) 
Time 
(Min) F1 F2 F3 F4 F5 F6 F7 F8 
0.25 4.90±0.11 5.62±0.27 5.07±0.76 5.54±1.28 5.91±1.81 3.66±0.32 4.19±0.29 3.99±0.18 
0.5 7.25±0.80 8.18±0.20 7.30±0.66 8.63±0.30 8.36±1.95 5.51±0.06 6.36±0.43 5.74±0.19 
1 13.05±1.38 13.06±0.20 10.33±0.02 12.19±0.87 13.43±2.90 9.37±0.47 10.98±2.96 7.93±0.13 
2 20.20±2.44 20.10±0.37 15.14±0.34 17.79±0.66 22.61±4.29 14.48±0.45 18.75±4.12 12.16±0.35 
4 27.64±3.40 28.31±0.16 19.48±0.47 23.74±0.71 34.63±2.38 21.91±2.18 28.96±0.81 18.41±0.44 
6 41.76±5.36 39.25±0.23 26.37±0.26 31.90±1.10 44.44±8.31 27.97±2.44 42.40±2.94 26.13±0.45 
8 50.06±7.58 48.88±0.30 33.60±0.67 40.19±1.29 53.30±7.97 36.12±4.00 52.70±3.67 34.97±0.27 
10 59.69±6.50 61.35±0.59 48.39±1.27 48.77±2.75 59.25±10.29 46.89±3.43 58.95±5.24 49.78±3.74 
24 75.71±1.47 88.18±1.76 64.48±1.22 69.06±1.76 97.65±0.70 58.75±1.03 79.10±1.14 59.45±0.86 
 
Figure 6: % Drug release profile of Aceclofenac Niosomal gel formulations (F1-F8) 
Table 5: % Entrapment efficiency and % Drug content after stability studies 
Number of Days % Entrapment Efficiency 
at temperatures 
% Drug Content 
at temperatures 
4±2oC 25±2oC 37±2oC 4±2oC 25±2oC 37±2oC 
15 91.8 91.63 91.29 97.65 97.19 96.81 
30 90.6 90.42 89.75 97.16 96.14 95.37 
45 90.27 88.67 84.54 96.23 95.28 94.18 
90 89.93 85.42 78.83 95.45 94.39 92.86 
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Figure 7: Entrapment efficiency of different formula-
tions	
pH	value	of	topical	niosomes	gel:	The	value	of	pH	of	topical	niosomal	gels	was	measured	by	using	digi-tal	 pH	 meter	 (LabindiaSab	 5000	 pH	 meter)	 at	 the	room	temperature.	The	pH	of	all	topical	niosomal	gels	was	found	to	be	in	the	range	of	7.4±0.02	to	7.4±0.08.	
In-vitro	 drug	 release	 study:	 The	 in-vitro	 release	study	in	phosphate	buffer	saline	pH	7.4	was	carried	out	using	Franz	diffusion	cell	according	to	procedure.	The	results	are	shown	in	below	tables.	
CONCLUSION	Aceclofenac	belongs	to	non-steroidal	anti-inflamma-tory	drug	 (NSAID)	 is	 considered	 to	be	 the	 first-line	drug	in	the	symptomatic	treatment	of	rheumatoid	ar-thritis,	osteoarthritis	and	ankylosing	spondylitis.	The	drug	is	having	a	narrow	therapeutic	index,	short	bio-logical	half-life	(about	4	h)	as	well	as	two	third	(70-80%)	of	the	dose	is	excreted	by	renal	transport	and	it	makes	aceclofenac	dosing	frequency	more	than	once	a	day.	As	this	dosage	form	would	reduce	the	dosing	frequency.	 In	 niosomes,	 the	 vesicles	 forming	 am-phiphile	 are	 a	 nonionic	 surfactant	 such	 as	 span	 60	which	is	usually	stabilized	by	addition	of	cholesterol.	Finally,	 it	can	be	concluded	from	the	results	of	pre-sent	study	that	niosome	gel	improve	the	transdermal	delivery,	 prolong	 the	 release,	 and	 improve	 the	 site	specificity	of	the	drug	Aceclofenac.	Niosomes	formed	with	F5	formulation	is	a	promising	approach	to	 im-prove	the	permeability	of	aceclofenac	in	a	period	of	time.	 Niosomes	 creates	 a	 new	 opportunity	 for	 the	well-controlled	transdermal	delivery	of	a	number	of	drugs	that	have	a	problem	of	administration	by	other	routes.	
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